Skadden is advising Hospira, Inc., a provider of injectable drugs and infusion technologies, on its $17 billion acquisition by Pfizer Inc., announced February 5.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is advising Hospira, Inc., a provider of injectable drugs and infusion technologies, on its $17 billion acquisition by Pfizer Inc., announced February 5.